May 23 2019
A team of researchers at Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, led by Professor Riichiro Abe and Assistant Professor Natsumi Hama identified, in collaboration with researchers at Department of Dermatology of Hokkaido University and other institutions, galectin-7 as a new diagnostic marker of Stevens-Johnson syndrome and toxic epidermal necrolysis, both of which are severe drug eruptions. This is expected to help make an early diagnosis of these severe skin reactions possible, potentially promoting the understanding of the pathogenesis of severe drug eruptions that have remained unknown to date.
Title: Galectin-7 as a potential biomarker of Stevens–Johnson syndrome/ toxic epidermal necrolysis: Identification by targeted proteomics using causative drug-exposed peripheral blood cells
Journal: The Journal of Allergy and Clinical Immunology: In Practice
Authors: Natsumi Hama, Keiko Nishimura, Akito Hasegawa, Akihiko Yuki, Hideaki Kume, Jun Adachi, Manao Kinoshita, Youichi Ogawa, Saeko Nakajima, Takashi Nomura, Hideaki Watanabe, Yoshiko Mizukawa, Takeshi Tomonaga, Hiroshi Shimizu, Riichiro Abe
Low Intake of Fruits and Vegetables Is Associated with Higher 10-Year Mortality Risk in Patients with Chronic Kidney Disease on Hemodialysis
New Drug Candidate for Spinocerebellar Ataxia ~Clinical Trial Results of L-Arginine for Spinocerebellar Ataxia Type 6~
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice